Zeta potential and particle size analyzer

Zeta potential and particle size analyzerIntroduction:

Upgraded from the original classic model 380ZLS, it adopts the principle of Dynamic Light Scattering (DLS) to detect and analyze the particle size distribution, with a particle size detection range of 0.3nm-10 μ m.

Zeta potential and particle size analyzertechnical advantage

1. High sensitivity PMT detector;

2. Can be paired with different power light sources;

3. High accuracy, close to the true value of the sample;

4. Can test the particle size and Zeta potential of water and organic phase samples;

5. Quick detection, able to trace historical data;

6. The result data is presented in various forms and formats;

7. Meets the requirements of multiple pharmacopoeias such as USP and CP;

8. No calibration required;

9. Composite algorithm:

(1) Free switching between Gaussian normal particle size distribution and Nicomp multimodal distribution algorithm for *

(2) Free switching between frequency Zeta potential analysis and phase analysis of *

10. Modular design facilitates maintenance and upgrades;

(1) Automatic dilution module (optional);

(2) Automatic sampling system (optional);

(3) Equipped with multi angle detector (optional);

Advantage: Modular design

The Nicomp Z3000 nano laser particle size analyzer is an advanced particle size analyzer that incorporates a multi module method based on the application of dynamic light scattering technology. With the upgrading and addition of modules, Nicomp's functional system is becoming increasingly powerful and can be used for detection and analysis of various complex systems.

Optional 21CFR Part 11 regulatory software - compliant with cGMP requirements

The Nicomp series of instruments are equipped with software that meets the requirements of 21 CFR PART11 in the United States. It has multiple functions such as automatic data backup, audit tracking, permission grading, electronic signature, and the ability to connect to the Lims system.

The China Food and Drug Administration (NMPA) has a policy trend to implement standardized GLP management for pharmaceutical research and development enterprises. Using software that complies with 21 CFR PART 11 regulations is more in line with current GLP/GMP requirements.